Abstract:e14536 Background: Adoptive T cells therapies have shown great potential over the past decade, particularly with the use of CAR-T cells to treat haematological tumors. However, their effect in the treatment of solid cancers is limited, due to a lack of relevant therapeutic targets and suppressive mechanisms of the tumor microenvironment. To counteract these challenges, we have developed Pan Cancer T (PCT) platforms to yield novel TCR-T cell therapies against untapped (intracellular) tumor targets exclusively expressed in 10 hard-to-treat solid tumors (including breast, melanoma, colorectal, glioma, lung cancer). Furthermore, we are developing engineering strategies aiming to improve the longevity of T cells within the inhibitory solid tumor microenvironment. Methods: The platforms we have developed to enable generation of genetically engineered TCR-T cells to recognize tumor-specific (intracellular) antigens include: 1) PCT Target Discovery (identifying and selecting safe, immunogenic tumor targets by combining advanced in silico and laboratory techniques); 2) PCT TCR Discovery (identifying, selecting, and validating potent TCR-T cells binding with high specificity and avidity); 3) PCT Next Gen Engineering (identifying drivers of immune evasion and implementing TCR-T cell-based gene-engineering approaches to overcome suppression and/or improve durability). Results: Using our PCT Target Discovery platform, we have validated a set of 30 unique tumor targets which are safe, immunogenic and highly shared. Our first showcase target is PCT-1, which is of particular interest in triple negative breast cancer (TNBC), where it is expressed by >85% of patients, with high homogeneity in >80% of all tumor cells. PCT-1 is also expressed in other tumor types, including >90% melanoma and >45% multiple myeloma patients. The PCT TCR Discovery platform has enabled development of a highly specific and active TCR against PCT-1, which outperformed standard of care TNBC treatments (ie, cis-platinum and sacituzumab govitecan) in advanced preclinical efficacy models, including in vitro killing of patient-derived 3D organoids and an in vivo model in NSG mice. Conclusions: The PCT platforms have enabled development of a promising TCR-T against a novel target antigen expressed in TNBC, an aggressive form of breast cancer that affects younger women with limited treatment options. A portfolio of 29 additional untapped targets has also been identified, providing potential to generate TCR-based therapies for treatment against a much larger range of solid tumors. Furthermore, we are developing next generation technologies, aiming to enhance the durability of responses within the hostile tumor microenvironment, which should be broadly applicable to TCR-T therapies.

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications

Triple-negative breast cancer: investigating potential molecular therapeutic target

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

Innovative platforms for development of TCR-T cell therapies against novel tumor targets: Triple negative breast cancer.

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis

Small molecule agents for triple negative breast cancer: Current status and future prospects

Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition

Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies

Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model

MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer

Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?

Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer

Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies

Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma

Novel Ways of Targeting Triple Negative Breast Cancer (TNBC) with the Latest Research - will it Improve Prognoses

Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer